Stock Analiz

Vistagen Therapeutics, Inc. VTGN

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$0.18Market cap $8M
Open the interactive analysis →

Vistagen Therapeutics, Inc. (VTGN) is a healthcare company listed in the US with a market value of about $8M. In the twelve months to September 30, 2026 it had revenue of $2M and net income of -$59M, a net margin of -2475.6%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -122%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 33% below the current price.

About Vistagen Therapeutics

Vistagen Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $1M in 2017 to $1M in 2026, growth of about 0.2% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 447% over three years (dilution for shareholders). It spends 4332% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth3/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S3.4
P/B0.5
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−33%

Growth and quality

Revenue growth (1 yr)161.1%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)592.6%
ROIC (5-yr avg.)-122.4%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2026202520242023202220212020201920182017
Revenue$2M$1M$486000$1M-$227000$1M———$0$1M
Net income-$59M-$70M-$51M-$29M-$59M-$48M-$11M-$12M-$25M-$14M-$10M
Free cash flow———-$26M-$50M-$45M——-$15M-$9M-$8M
EPS (diluted)$-1.36$-1.83$-1.67$-1.52$-8.51$-7.38——$-0.90$-1.12$-1.54
Net margin-2475.6%-5491.3%-10579.8%-2759.6%26100.4%-4306.8%————-820.4%
ROIC—-155.8%-61.5%-22.4%-316.6%-55.7%——-272.0%-160.9%-1207.3%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 2 analysts is $1.00, 454% above the current price; targets range from $1.00 to $1.00; the consensus rating is “Hold”; expected EPS is $-1.48 for the fiscal year ending March 31, 2027.

Frequently asked questions

Is Vistagen Therapeutics stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 33% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Vistagen Therapeutics pay a dividend?

Not currently.

Is Vistagen Therapeutics a good stock to buy?

We do not give buy or sell advice. Vistagen Therapeutics scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.